Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

safety and efficacy of CDP-1050, the availability of CDP-1050 worldwide to treat ill heart failure patients, ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, and CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... for Molecular Medicine Finland (FIMM), University of Helsinki, ... "man and machine" decision support system for diagnosing ... in PLOS One scientific journal today, ... vision algorithms similar to those used in facial ... diagnostically most relevant areas. Tablet computers can be ...
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
(Date:8/21/2014)... New Rochelle, N.Y. (PRWEB) August 21, 2014 ... it is the first private college in the Mid-Hudson ... The College will now begin accepting applications from qualified ... , “We are very pleased to have been ... to support Governor Cuomo’s transformative initiative to stimulate economic ...
(Date:8/21/2014)... , Aug. 21, 2014 ... Immune Pharmaceuticals Inc., a biotechnology company, on its ... Immune previously traded on OTCQX®, the best marketplace ... OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... on the successful execution of its growth strategy ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Vical Incorporated (Nasdaq:,VICL) today reported financial results for the quarter ... were $0.8 million, compared,with revenues of $0.4 million for the ... of 2008 was $9.8 million or $0.24 per share, compared,with ... of 2007., Revenues for the first nine months of ...
... - New business awards of $212 million, up 21% from third ... 2008, up 16% ... from Dec. 31, 2007, CINCINNATI, Nov. 4 Kendle ... income of $11.0 million or $0.73 per diluted share for its third,quarter ended ...
... Nov. 4 Danaher Corporation (NYSE:,DHR) announced that ... Comas will be presenting at the Robert W. ... 12, 2008 at 1:55 p.m. CST.,The audio will ... Danaher Corporation is a leading manufacturer of Professional,Instrumentation, ...
Cached Biology Technology:Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 6Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 2Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 3Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 4Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 5Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 6Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 7Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 8
(Date:8/21/2014)... from North Carolina State University have developed a novel ... model has applications for creating new materials as well ... "Our new technique allows us to model much larger ... much more quickly," says Nan Li, lead author of ... in NC State,s Department of Materials Science and Engineering. ...
(Date:8/20/2014)... George E. Fox, a John and Rebecca Moores Professor of ... named a fellow in the International Society for the Study ... one of four members two from the U.S., one ... in 2014. Fellows are elected every three years, and 36 ... from more than 20 countries, the ISSOL includes researchers from ...
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... has been intimately entwined since Lon Foucault discovered the speed ... more slowly in water than in air. This physical harmony ... and drive light to where it can be the most ... optofluidics, the study of microfluidicsthe microscopic delivery of fluids through ...
... induced pluripotent stem cells were first derived in 2007, scientists ... cells, which are sourced in early-stage embryos. Both cell ... the body, but their origins in embryonic and adult ... both cell types have great potential in basic biological research ...
... Homeowners and taxpayers are picking up most of the ... inadvertently imported along with packing materials, live plants, and other ... economists, whose research findings are reported in the journal ... that non-native, wood-boring insects such as the emerald ash borer ...
Cached Biology News:A guiding light for new directions in energy production 2A guiding light for new directions in energy production 3Study reveals critical similarity between two types of do-it-all stem cells 2Study reveals critical similarity between two types of do-it-all stem cells 3Invasive forest insects cost homeowners, taxpayers billions 2
... , Maintenance 112 days/each , ... Immunizations/Boost injections x5 /each , ... , Production bleed (25 ml blood =12 ml ... ml blood (~50 ml serum) x1 each , ...
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
muscle actin (HUC1-1)...
Biology Products: